share_log

JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30

Benzinga ·  Jul 31 14:32  · Ratings

JP Morgan analyst Robbie Marcus maintains AtriCure (NASDAQ:ATRC) with a Overweight and lowers the price target from $34 to $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment